Regeneus Limited (ASX:RGS) CEO Leo Lee presents on the company's 1H19 results, its portfolio of novel cell-based therapies, progress with its Phase 2 trial of Progenza and strategy at FNN's Investor Event.
- A clinical-stage regenerative medicine company
- Portfolio of innovative cellular therapies
- These target significant unmet medical needs with a licence-driven strategy
- Focus on osteoarthritis and other musculoskeletal disorders
- Focus on neuropathic pain and dermatology
- Lead drug in knee osteoarthritis (US$5 billion addressable market)
For more, watch CEO Leo Lee present.